What is Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN) share price return in the past 10 years?

Data is not available for this company

What is the share price of Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)?

Company share prices are keep on changing according to the market conditions. The current trading price of Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the market cap of Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 at 05:30, the market cap of Dishman Pharmaceuticals & Chemicals . - (Amalgamated) stood at Rs. 4858.77 Cr.

What is the P/E ratio of Dishman Pharmaceuticals & Chemicals . - (Amalgamated)?

The latest standalone P/E ratio of Dishman Pharmaceuticals & Chemicals . - (Amalgamated) as of 01-Jan-1970 is 74.11.

What is the 52-week high and low of Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)?

The 52-week high of Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN) is Rs. 304.30 and the 52-week low is Rs. 278.10.

What is the TTM revenue of Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dishman Pharmaceuticals & Chemicals . - (Amalgamated) is Rs. 416.79 (Cr.).

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)
Brand: Dishman Pharmaceuticals & Chemicals . - (Amalgamated)

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532526 NSE: DISHMAN Pharmaceuticals & Drugs | Small Cap | Dishman Pharma(Amalg Share Price

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532526 NSE: DISHMAN Pharmaceuticals & Drugs | Small Cap | Dishman Pharma(Amalg Share Price

Key Metrics

Valuation Multiples

Market Cap

₹4,859 Cr.

Current Price

₹0

52-Week Low / High

₹278 / 304

TTM EPS

₹4.1

TTM Sales

₹417 Cr.

Book Value per Share

₹295.5

P/E Ratio

74.11

Industry PE

46.5

Price to Book (P/B)

1.02

Price to Sales (P/S)

11.66

EV/EBITDA

26.40

Dividend Yield

0.60%

Profitability Efficiency

Return on Equity (ROE)

9.99%

Return on Capital Employed (ROCE)

12.57%

Return on Assets (ROA)

4.72%

Operating Profit Margin

33.5%

Net Profit Margin

17.08%

Gross Profit Margin

31.9%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

3.69%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

15.26%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

49.03%

Asset Quality

Promoter Holding

61.40%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹4,737 Cr.

Equity

₹32.3 Cr.

Face Value

₹2

All Time Low / High

₹16.25 / 346.25

Dishman Pharmaceuticals & Chemicals . - (Amalgamated) stock performance

Key Ratios

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	TTM
ROCE % ⓘ	14.1%	12.9%	15.7%	11.6%	7.9%	10.6%	12.3%	14.7%	12.4%	12.6%	-
Growth Parameters ⓘ
Sales ⓘ	275	359	416	353	421	463	485	473	492	510	417
Sales YoY Gr.	-	30.5%	15.8%	-15.2%	19.3%	10.1%	4.6%	-2.3%	4%	3.7%	-
Adj EPS ⓘ	3.8	3.7	6.3	4.3	2.4	3.2	4.1	5.3	3.3	5.2	4.1
YoY Gr.	-	-1.9%	71.5%	-32.7%	-43.2%	31%	30.3%	28.3%	-38.1%	59.2%	-
BVPS (₹) ⓘ	18.5	28.3	34	37.8	39.6	41.6	44.8	49.3	51.7	56.4	295.5
Adj Net Profit ⓘ	54.2	58.9	102	68.8	39.1	51.1	66.7	85.6	53	84.2	66
Cash Flow from Ops. ⓘ	21.2	42.5	90.8	110	118	250	28.3	126	14.5	125	-
Debt/CF from Ops. ⓘ	14.1	6.2	3.2	4	4.8	2	18.5	4.2	43.4	5	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.1%	3.9%	1.7%	3.7%
Adj EPS ⓘ	3.7%	16.6%	8.1%	59.2%
BVPSⓘ	13.2%	7.3%	7.9%	9%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	TTM
Return on Equity % ⓘ	24.6	16.3	20.3	11.8	6.2	7.8	9.5	11.2	6.5	9.6	2.3
Op. Profit Mgn % ⓘ	25.7	25.6	36.1	33.3	24	33.4	36	37.2	30.1	33.5	32.5
Net Profit Mgn % ⓘ	19.7	16.4	24.6	19.5	9.3	11	13.8	18.1	10.8	16.5	15.7
Debt to Equity ⓘ	1.1	0.6	0.5	0.7	0.9	0.7	0.7	0.7	0.8	0.7	-
Working Cap Days ⓘ	325	307	270	347	417	436	406	467	564	638	287
Cash Conv. Cycle ⓘ	183	168	133	101	79	61	53	50	85	91	118

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Sales	275.24	359.20	415.88	352.61	420.82	463.40	484.64	473.29	492.24	510.39
Operating Expenses ⓘ +	204.53	272	279.48	235.34	320.13	318.52	315.49	297.07	344.07	339.61
Manufacturing Costs	31.62	34.90	41.34	42.58	42	44.86	49.23	42.23	49.18	53.81
Material Costs	133.21	183.82	172.05	138.15	210.45	195.22	179.20	175.72	213.84	194.50
Employee Cost	18.05	24.60	25.28	28.64	47.10	45.22	58.21	58.38	58.88	65.89
Other Costs ⓘ	21.64	28.68	40.81	25.97	20.59	33.21	28.85	20.74	22.17	25.41
Operating Profit ⓘ	70.72	87.20	136.40	117.27	100.69	144.88	169.14	176.21	148.17	170.78
Operating Profit Margin (%)	25.7%	24.3%	32.8%	33.3%	23.9%	31.3%	34.9%	37.2%	30.1%	33.5%
Other Income ⓘ +	16.01	11.99	5.40	12.69	16.39	11.84	13.63	55.98	67.91	62.38
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	7.69	9.76	26.96	29.91	40.53	57.54	52.74	69.22	68.13	68.66
Depreciation ⓘ	14.24	16.82	19.79	20.64	28.01	31.66	35.34	44.13	44.13	44.25
Profit Before Tax ⓘ	64.80	72.61	95.06	79.41	48.54	67.52	94.70	118.84	103.82	120.25
Tax ⓘ	2.89	11.23	2.50	9.04	8.41	22.68	31.52	32.05	45.34	33.10
Profit After Tax	61.91	61.38	92.56	70.37	40.12	44.84	63.18	86.79	58.48	87.15
PAT Margin (%)	22.5%	17.1%	22.3%	20.0%	9.5%	9.7%	13.0%	18.3%	11.9%	17.1%
Adjusted EPS (₹)	4.3	3.9	5.7	4.4	2.5	2.8	3.9	5.4	3.6	5.4
Dividend Payout Ratio (%)	11.70%	13%	10.50%	13.80%	24.10%	21.60%	15.30%	11.20%	27.60%	18.50%

Valuation of Dishman Pharma(Amalg - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Equity and Liabilities
Shareholders Fund +	269.24	453.79	553.62	612.96	641.38	673.63	725.41	797.08	836.43	911.50
Share Capital ⓘ	14.44	15.94	16.14	16.14	16.14	16.14	16.14	16.14	16.14	16.14
Reserves ⓘ	254.79	437.85	537.48	596.82	625.24	657.49	709.28	780.94	820.29	895.36
Debt +	298.45	262.51	290.52	434.06	488.55	429.69	459.04	416.46	505.55	542.51
Long Term Debt	298.45	262.51	290.52	434.06	308.91	301.68	274.53	239.74	242.96	274.43
Short Term Debt	0	0	0	0	179.65	128.01	184.51	176.72	262.59	268.08
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	40.64	46.27	22.92	75.06	119.01	84.93	95.27	83.63	99.59	76.10
Others Liabilities ⓘ	80	62.66	43.73	58.67	228.53	253.43	219.33	259.65	376.51	344.54
Total Liabilities ⓘ	688.33	825.22	910.79	1,180.76	1,477.47	1,441.68	1,499.05	1,556.81	1,818.08	1,874.65
Fixed Assets
Net Fixed Assets ⓘ +	205.08	255.63	268.60	353.84	486.77	470.32	682.55	694.61	693.62	669.63
Gross Block	259.78	326.33	358.73	464.18	624.64	639.35	886.14	942.27	986.48	1,006.35
Accumulated Depreciation	54.70	70.70	90.13	110.34	137.86	169.02	203.59	247.65	292.86	336.72
CWIP ⓘ	49.10	110.62	172.96	267.64	198.96	257.34	48.79	9.86	10.15	22.14
Investments ⓘ	131.29	132.51	156.37	181.99	187.14	187.06	187.06	187.06	210.16	250.78
Inventories	98.65	120.63	116.32	99.75	124.25	119.13	127.76	133.86	171.90	145.37
Trade Receivables	120.72	111.50	61.55	70.24	126.97	96.46	62.79	69.42	97.65	87.87
Cash Equivalents	4.95	4.49	3.20	4.28	4.31	6.45	10.89	11.26	22.62	9.27
Others Assets ⓘ	78.53	89.85	131.78	203.01	349.07	304.92	379.21	450.75	611.98	689.59
Total Assets ⓘ	688.33	825.22	910.79	1,180.76	1,477.47	1,441.68	1,499.05	1,556.81	1,818.08	1,874.65

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Cash Flow From Operating Activity ⓘ +	21.17	42.45	90.83	109.64	117.89	249.72	28.29	125.70	14.51	124.94
PBT ⓘ	64.80	72.61	95.06	79.41	48.54	67.52	94.70	118.84	103.83	120.25
Adjustment ⓘ	15.64	13.36	47.15	40.54	54.17	77.17	80.47	54.14	54.22	53.35
Changes in Working Capital ⓘ	-54.01	-35.08	-41.31	5.73	24.94	112.61	-130.57	-22.21	-112.68	-7.77
Tax Paid ⓘ	-5.18	-8.36	-9.94	-17.14	-9.75	-7.59	-16.30	-25.06	-30.86	-40.89
Cash Flow From Investing Activity ⓘ +	-194.49	-118.98	-100.51	-213.69	-190.76	-52.26	5.67	-47.54	-35.81	-30.22
Capex	-80.03	-128.86	-79.65	-196.89	-197.22	-43.74	11.84	-92.93	-59.21	-38.83
Net Investments	-119.26	7.23	0	0.05	0	0.96	0	0	3.02	0
Others ⓘ	4.79	2.65	-20.86	-16.85	6.47	-9.48	-6.17	45.39	20.38	8.61
Cash Flow From Financing Activity ⓘ +	54.23	76.07	8.39	105.13	72.89	-195.32	-29.84	-78.44	25.37	-102.44
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	162.70	37.33	-66.47	-59.25	10	19.38	-5.94
Interest Paid ⓘ	-6.11	-9.76	-31.69	-33.14	-39.97	-55.13	-52.52	-69.39	-68.55	-69.73
Dividend Paid ⓘ	-4.82	-7.63	-8.07	-9.68	-9.68	-9.68	-9.68	-9.68	-9.68	-32.27
Others ⓘ	65.16	93.46	48.16	-14.74	85.22	-64.03	91.61	-9.36	84.22	5.50
Net Cash Flow ⓘ	-119.08	-0.46	-1.29	1.08	0.03	2.14	4.12	-0.28	4.07	-7.72

Financial Ratio

PARTICULARS	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16
Ratios
ROE (%)	28.44	17.1	18.5	12.13	6.42	6.84	9.05	11.43	7.17	9.99
ROCE (%)	14.11	12.88	15.71	11.6	7.93	10.59	12.25	14.65	12.35	12.57
Asset Turnover Ratio	0.46	0.49	0.49	0.34	0.32	0.32	0.33	0.31	0.29	0.28
PAT to CFO Conversion(x)	0.34	0.69	0.98	1.56	2.94	5.57	0.45	1.45	0.25	1.43
Working Capital Days
Receivable Days	128.40	115.30	74.50	67.30	84.50	86.90	59.30	50.40	61.40	65.60
Inventory Days	118.70	108.90	102	110.30	95.90	94.70	91.90	99.70	112.30	112.20
Payable Days	103	86.30	73.40	129.40	168.30	190.60	183.50	185.80	156.40	164.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

35.76

30.31

17.26

11.46

2.46

2.42

0.57

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) FAQs

The current trading price of Dishman Pharma(Amalg on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Dishman Pharma(Amalg stood at ₹4,858.8 Cr

The latest P/E ratio of Dishman Pharma(Amalg as of 31-Dec-1969 is 74.11.

The latest P/B ratio of Dishman Pharma(Amalg as of 31-Dec-1969 is 1.02.

The 52-week high of Dishman Pharma(Amalg is ₹304.3 and the 52-week low is ₹278.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dishman Pharma(Amalg is ₹417 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) is a average quality company.

No data found

About Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the â€œQuat Companyâ€. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year 1995, the company entered into a joint ventured with SchÃ¼tz & Co, Germany and formed SchÃ¼tz Dishman Biotech. This company manufactures Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution to cater European market. In 1995-96, the company expanded its activities for the development of many intermediates and APIs. In 1998 in order to penetrate in European and US market, the company formed two wholly-owned subsidiaries Dishman Europe and Dishman USA Inc. In 1998, the company forayed into contract research and manufacture sector. Within a period of 5 years DPCL was able to several contract research and manufacturing projects and later emerged as Indiaâ€™s leading CMO organization (Contract Manufacturing Outsourcing).

Headquartered at Ahmedabad, the company owns three manufacturing units, two located at Bavla and one at Naroda. Presently the company is manufactures a range of Bulk APIs, Intermediates, Specialties and Quats. The company has representative office located at Germany, Italy and Turkey.

DPCL is engaged in the manufacture of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals. It provides a range of products to the global market, including a range of reagents, specialty chemicals, APIs and their intermediates.

Business units:

Dishman Specialty Chemicals, which manufactures Phase Transfer Catalysts;

Dishman Vitamins and Chemicals, which manufactures Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and laolin related products for pharmaceutical, cosmetic and related markets,

Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations.

The products manufactured by the company include bulk drugs, phase transfer catalyst and fine chemicals

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Dishman Pharmaceuticals & Chemicals . - (Amalgamated) stock performance

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Dishman Pharma(Amalg - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) FAQs

About Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) (DISHMAN)

Dishman Pharmaceuticals & Chemicals . - (Amalgamated) stock performance

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Dishman Pharma(Amalg - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) FAQs

What is the share price of Dishman Pharma(Amalg?

What is the market cap of Dishman Pharma(Amalg?

What is the P/E ratio of Dishman Pharma(Amalg?

What is the P/B ratio of Dishman Pharma(Amalg?

What is the 52-week high and low of Dishman Pharma(Amalg?

What is the TTM revenue of Dishman Pharma(Amalg?

Is a good quality company?

Is undervalued or overvalued?

Is a good buy now?

About Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated)

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.